Solaredge Technologies Inc vs Zimmer Biomet Holdings Inc — how do they compare? Solaredge Technologies Inc trades at $32.1 (market cap $2.05B), while Zimmer Biomet Holdings Inc trades at $97.03 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 9× Solaredge Technologies Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.
| SEDG | ZBH | |
|---|---|---|
Market Cap | $2.05B | $18.55B |
Sector | Technology | Health |
52-Week High | $78.51 | $107.71 |
52-Week Low | $25.10 | $79.58 |
Enterprise Value | $1.91B | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
SolarEdge Technologies (SEDG) trades at $32.04, down 0.53% on the day, reflecting ongoing volatility amid mixed financial performance. The stock exhibits a bearish technical trend, with negative profitability metrics including a net income margin of -20.29% and ROE of -58.42% for 2026. Recent Q2 2026 earnings beat expectations with EPS of $0.06, but weak Q3 revenue guidance has pressured shares. Cash flow improved in 2025 with net cash flow of $138.60 million, though debt levels remain elevated.
The outlook is cautious due to persistent losses, high dependence on policy incentives, and a challenging U.S. residential solar market. Analyst consensus is mixed with a hold-heavy rating (58.34%) and a $35.15 price target, suggesting limited near-term upside. Key risks include execution missteps, competitive pressures, and macroeconomic headwinds, requiring careful monitoring of margin recovery and demand trends.
Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.
The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →